Hormone replacement therapy (HRT) replaces estrogen, progesterone or testosterone to treat menopause symptoms and low testosterone. For healthy women under 60 or within 10 years of menopause, The Menopause Society (2022) finds the benefits outweigh the risks.
Bremelanotide (PT-141, sold as Vyleesi) is an FDA approved on demand injection for low sexual desire in premenopausal women that works on brain melanocortin receptors rather than blood flow. In phase 3 trials about 25% of women reported a meaningful rise in desire, versus 17% on placebo.
TB-500 is a synthetic fragment of thymosin beta-4 that promotes tissue repair through cell migration, new blood vessel formation, and inflammation control. Here is what the research shows for injuries, cardiac repair, hair regrowth, and how it compares to BPC-157.
Peptide safety depends on which peptide, its source, the dose and medical supervision. Semaglutide and tirzepatide have FDA approval and large trials, while the FDA says it lacks human safety data for compounded BPC-157 and TB-500.
Testosterone is the hormone that quietly runs the show for men’s health. It affects everything from your energy levels and mood to your muscle mass, bone density, and sex drive. When levels drop below where they should be, the effects can feel like a slow fade: less motivation, more belly fat, poor sleep, and a…
Most HRT side effects are mild and settle within one to three months. Serious risks such as blood clots, stroke and breast cancer depend mainly on the estrogen route, the progestogen used and starting within 10 years of menopause.
Everything you need to know about peptide therapy — BPC-157, thymosin alpha-1, CJC/ipamorelin, GHK-Cu, Semax, and more. How they work, what the evidence shows, protocols, costs, safety, and the regulatory landscape.
Hormonal acne is driven by androgens such as DHT, often amplified by insulin and IGF-1, and shows as deep jawline and chin breakouts. Spironolactone, combined pills, clascoterone and isotretinoin target it, with spironolactone beating placebo in the SAFA trial (BMJ, 2023).
